New drug combo aims to halt scleroderma skin damage
NCT ID NCT03844061
First seen Apr 24, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study tests whether adding two immune-suppressing drugs (belimumab and rituximab) to standard therapy can improve skin fibrosis in people with early, severe diffuse scleroderma. About 30 adults will receive either the drug combination or placebo injections, while all continue taking mycophenolate. The main goal is to see if the combination reduces skin hardening and improves overall disease activity over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital for Special Surgery
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.